{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:05:45Z","timestamp":1784761545223,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["Project no. PE00000007, INF-ACT"],"award-info":[{"award-number":["Project no. PE00000007, INF-ACT"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fungal infections are common worldwide and a frequent reason for pediatric primary care visits, mainly affecting the skin, hair, and nails, with a consistently high prevalence in outpatient settings. This study aimed to assess the burden of fungal infections in pediatric primary care in Italy and characterize the patterns of antifungal therapy use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This population database analysis used data from Pedianet, a comprehensive database of 193 family pediatricians in Italy. The annual incidence rate (IR) of fungal infections was evaluated in children aged\u2009&lt;\u200914 years from January 2010 to December 2024. Subjects were followed up from 2010 or their enrollment date until the end of assistance or the end of the study period. All antifungal treatments occurring within an episode were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 23,463 episodes of fungal infection were identified, including 23,034 episodes of skin and mucocutaneous mycoses and 429 episodes of onychomycosis. The most frequent diagnoses were\n                      <jats:italic>Candida<\/jats:italic>\n                      -associated diaper dermatitis (52.1%) and mucocutaneous candidiasis (27.4%). Between 2010 and 2019, the incidence of fungal infections remained stable at 11\u201314 cases per 1,000 person-years. A marked decline across all age groups was observed in 2020, reflecting the impact of the SARS-CoV-2 pandemic. Regarding treatment, 144\/429 (33.6%) of onychomycosis episodes received an antifungal prescription, mainly tioconazole, while 8347\/23,034 (36.3%) of skin and mucocutaneous mycoses were treated, predominantly with clotrimazole.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This population-based cohort study updates the epidemiology of non-invasive fungal infections in pediatric outpatients and underscores the need for greater awareness, improved diagnosis, prevention, and antifungal stewardship in primary care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13052-026-02277-8","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:55:17Z","timestamp":1779796517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden of non-invasive fungal infections and antifungal therapy in pediatric primary care settings: FUNGICARE Project"],"prefix":"10.1186","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9633-873X","authenticated-orcid":false,"given":"Lorenzo","family":"Chiusaroli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelyne","family":"Gres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Cozzolino","family":"Cangiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cantarutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Don\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2277_CR1","doi-asserted-by":"crossref","unstructured":"Casalini G, Giacomelli A, Antinori S. The WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation. Lancet Microbe. Elsevier Ltd; 2024. pp. 717\u201324.","DOI":"10.1016\/S2666-5247(24)00042-9"},{"key":"2277_CR2","unstructured":"U.S. Center fo Disease Control and Prevention (CDC). Fungal disease burden by the numbers [Internet]. 2025 [cited 2025 Nov 8]. Available from: https:\/\/www.cdc.gov\/fungal\/data-research."},{"key":"2277_CR3","doi-asserted-by":"crossref","unstructured":"Wang H, Sun F, Wang C, et al. A systematic analysis of the global, regional, and national burden of fungal skin diseases from 1990 to 2021. Front Epidemiol. 2024;4.","DOI":"10.3389\/fepid.2024.1489148"},{"key":"2277_CR4","doi-asserted-by":"crossref","unstructured":"Li D, Fan S, Zhao H, et al. Worldwide trends and future projections of fungal skin disease burden: a comprehensive analysis from the Global Burden of Diseases study 2021. Front Public Health. 2025;13.","DOI":"10.3389\/fpubh.2025.1580221"},{"key":"2277_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jdin.2020.10.003","volume":"2","author":"K Urban","year":"2021","unstructured":"Urban K, Chu S, Scheufele C, et al. The global, regional, and national burden of fungal skin diseases in 195 countries and territories: A cross-sectional analysis from the Global Burden of Disease Study 2017. JAAD Int. 2021;2:22\u20137.","journal-title":"JAAD Int"},{"issue":"2","key":"2277_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mycmed.2013.11.004","volume":"24","author":"GCM Batista","year":"2014","unstructured":"Batista GCM, Krebs VLJ, Ruiz LS, et al. Oral colonization: A possible source for candidemia in low-weight neonates. J Mycol Med. 2014;24(2):81\u20136.","journal-title":"J Mycol Med"},{"key":"2277_CR7","doi-asserted-by":"crossref","unstructured":"Hay R. Therapy of skin, hair and nail fungal infections. J Fungi (Basel). MDPI AG;2018.","DOI":"10.3390\/jof4030099"},{"key":"2277_CR8","doi-asserted-by":"crossref","unstructured":"Benedict K, Tsay SV, Bartoces MG, et al. Outpatient antifungal prescribing patterns in the United States, 2018. Antimicrob Steward Healthc Epidemiol. 2021;1(1).","DOI":"10.1017\/ash.2021.201"},{"key":"2277_CR9","doi-asserted-by":"crossref","unstructured":"Rychlik K, Sternicka-Rohde J, Nowicki RJ, et al. Superficial fungal infections in children\u2014what do we know? J Clin Med. 2025.","DOI":"10.3390\/jcm14207380"},{"key":"2277_CR10","doi-asserted-by":"crossref","unstructured":"Cantarutti AGC. Pedianet database. In: Databases for Pharmacoepidemiological Research. Cham (CH): Springer; 2021. p. 159-164.","DOI":"10.1007\/978-3-030-51455-6_13"},{"issue":"12","key":"2277_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/1346-8138.15618","volume":"47","author":"T Mochizuki","year":"2020","unstructured":"Mochizuki T, Tsuboi R, Iozumi K, et al. Guidelines for the management of dermatomycosis. J Dermatol. 2020;47(12):1343\u201373.","journal-title":"J Dermatol"},{"key":"2277_CR12","doi-asserted-by":"crossref","unstructured":"Gupta AK, Versteeg SG, Shear NH. Onychomycosis in the 21st century: an update on diagnosis, epidemiology, and treatment. J Cutan Med Surg. 2017:525\u201339.","DOI":"10.1177\/1203475417716362"},{"key":"2277_CR13","unstructured":"Division of Cancer Control and Population Sciences NCI. Joinpoint trend analysis software [Internet]. 2025 [cited 2026 Mar 9]. Available from: https:\/\/surveillance.cancer.gov\/joinpoint\/."},{"issue":"6","key":"2277_CR14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/jid.2013.446","volume":"134","author":"RJ Hay","year":"2014","unstructured":"Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions. J Invest Dermatology. 2014;134(6):1527\u201334.","journal-title":"J Invest Dermatology"},{"key":"2277_CR15","first-page":"204","volume":"1","author":"D Seth","year":"2017","unstructured":"Seth D, Cheldize K, Brown D, et al. Global Burden of Skin Disease: Inequities and Innovations. Curr Dermatol Rep Curr Med Group LLC. 2017;1:204\u201310.","journal-title":"Curr Dermatol Rep Curr Med Group LLC"},{"key":"2277_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/antibiotics9080445","volume":"9","author":"Gina Wall","year":"2020","unstructured":"Gina Wall. Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy. Antibiotics. 2020;9:445.","journal-title":"Antibiotics"},{"issue":"4","key":"2277_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.4103\/ijabmr.IJABMR_207_20","volume":"10","author":"M Kaur","year":"2020","unstructured":"Kaur M, Gupta A, Mahajan R, et al. Efficacy, safety, and cost evaluation of the topical luliconazole therapy versus topical clotrimazole therapy in patients with localized dermatophytosis in a tertiary care hospital: An observational study. Int J Appl Basic Med Res. 2020;10(4):260.","journal-title":"Int J Appl Basic Med Res"},{"key":"2277_CR18","doi-asserted-by":"crossref","unstructured":"Axler E, Lipner SR. Antifungal selection for the treatment of onychomycosis: patient considerations and outcomes. Infect Drug Resist. 2024:819\u201343.","DOI":"10.2147\/IDR.S431526"},{"key":"2277_CR19","doi-asserted-by":"crossref","unstructured":"Kruithoff C, Gamal A, McCormick TS, et al. Dermatophyte infections worldwide: increase in incidence and associated antifungal resistance. Multidisciplinary Digital Publishing Institute (MDPI); 2024.","DOI":"10.20944\/preprints202311.1060.v1"},{"key":"2277_CR20","doi-asserted-by":"crossref","unstructured":"Sedik S, Egger M, Hoenigl M. Climate change and medical mycology. Infect Dis Clin North Am. 2025:1\u201322.","DOI":"10.1016\/j.idc.2024.11.002"},{"key":"2277_CR21","doi-asserted-by":"crossref","unstructured":"Chiusaroli L, Cozzolino C, Cocchio S, et al. Epidemiological analysis of fungal infection disease in pediatric population: focus on hospitalization from 2007 to 2022 in Veneto Region in Italy. Pathogens. 2025;14(1).","DOI":"10.3390\/pathogens14010093"},{"key":"2277_CR22","unstructured":"Good Clinical Practice and Helsinki declaration [Internet]. Available from: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/."},{"key":"2277_CR23","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Methodological Guide [Internet]. 2023 [cited 2026 Jan 23]. Available from: https:\/\/encepp.europa.eu\/encepp-toolkit\/methodological-guide_en."}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-026-02277-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-026-02277-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-026-02277-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:49:44Z","timestamp":1784760584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13052-026-02277-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2277"],"URL":"https:\/\/doi.org\/10.1186\/s13052-026-02277-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8670391\/v1","asserted-by":"object"}]},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is an observational, retrospective, non-interventional study. According to a bylaw on the classification and implementation of observational drug-related research, as issued by the Italian National Drug Agency (an entity belonging to the Italian Ministry of Health), this study does not require approval by an ethics committee in Italy (Italian Drug Agency note on August 3, 2007). This study was conducted in accordance with the tenets of the Declaration of Helsinki and was compliant with the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance\u2019s Guide on Methodological Standards in Pharmacoepidemiology [\n                      \n                      ,\n                      \n                      ]. Written informed consent to participate in this study was provided by the participants\u2019 legal guardian\/next of kin.","order":1,"name":"Ethics","label":"Ethical approval and consents to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval of the study and access to the database was approved by the Internal Scientific Committee of Societ\u00e0 Servizi Telematici. Srl, the legal owner of Pedianet. The corresponding author confirms that he had full access to all the data in the study and was finally responsible for the decision to submit it for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Table\n                      \n                      : Complete list of fungal infections and adverse events codes considered. Table\n                      \n                      : Complete findings regarding the treatment prescription and the treatment outcome. Figure\n                      \n                      : Trend of fungal infection episodes stratified for the age of patients. Figure\n                      \n                      : Sankey diagram presents the antifungal treatment switching during the skin and mucocutaneous episodes.","order":3,"name":"Ethics","label":"Supplementary materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted without commercial or financial relationships that could be construed as potential conflicts of interest. The authors have no conflict of interest to declare. We affirm that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of any organization or company.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"114"}}